Most sold healthcare stocks in Q2 2026
Discover which Healthcare stocks institutional investors trimmed or exited the most over Q2 2026 versus the prior calendar quarter in our filings. Notable reductions at the top of this list include PFIZER INC (PFE), MERCK & CO. INC. (MRK), JOHNSON & JOHNSON (JNJ), BRISTOL-MYERS SQUIBB CO (BMY). These rankings aggregate SEC 13F filings from all institutional investors in our database.
Net share decreases
Top symbols by net quarter-over-quarter share change (decreases).
Most sold stocks
Net quarter-over-quarter share reductions across all institutional filers.
| Symbol | Name | Net shares | Net value | New | Added | Trimmed | Sold out | Holding now |
|---|---|---|---|---|---|---|---|---|
| PFE | PFIZER INC | -3,628,261,683 | -$98.3B | 19 | 225 | 237 | 2363 | 548 |
| MRK | MERCK & CO. INC. | -1,822,680,967 | -$210.0B | 33 | 339 | 304 | 2920 | 788 |
| JNJ | JOHNSON & JOHNSON | -1,657,266,870 | -$390.4B | 34 | 442 | 420 | 3574 | 1007 |
| BMY | BRISTOL-MYERS SQUIBB CO | -1,483,217,041 | -$85.4B | 25 | 199 | 194 | 2013 | 491 |
| ABT | ABBOTT LABORATORIES | -1,312,054,146 | -$130.7B | 29 | 211 | 282 | 2462 | 598 |
| BSX | BOSTON SCIENTIFIC CORP | -1,281,626,440 | -$77.9B | 20 | 68 | 89 | 1456 | 204 |
| ABBV | ABBVIE INC | -1,207,104,094 | -$252.3B | 68 | 409 | 314 | 3146 | 896 |
| CVS | CVS HEALTH CORP | -1,049,429,048 | -$71.7B | 57 | 144 | 134 | 1508 | 389 |
| GILD | GILEAD SCIENCES INC | -1,007,751,464 | -$133.6B | 21 | 181 | 147 | 1886 | 415 |
| VTRS | VIATRIS INC | -963,881,690 | -$11.7B | 13 | 56 | 39 | 857 | 156 |
| LLY | ELI LILLY & CO | -747,642,916 | -$658.7B | 75 | 450 | 294 | 3425 | 944 |
| UNH | UNITEDHEALTH GROUP INC | -712,345,889 | -$181.2B | 88 | 261 | 233 | 2417 | 636 |
| AVTR | AVANTOR INC | -664,329,103 | -$5.0B | 11 | 18 | 7 | 392 | 44 |
| TEVA | TEVA PHARMACEUTICAL-SP ADR | -649,709,163 | -$16.1B | 11 | 34 | 17 | 563 | 89 |
| HLN | HALEON PLC-ADR | -547,590,964 | -$5.3B | 7 | 21 | 31 | 521 | 97 |
| ELAN | ELANCO ANIMAL HEALTH INC | -538,231,923 | -$11.9B | 5 | 17 | 25 | 454 | 60 |
| DHR | DANAHER CORP | -538,100,020 | -$96.0B | 25 | 105 | 194 | 1780 | 379 |
| BAX | BAXTER INTERNATIONAL INC | -520,474,253 | -$8.5B | 16 | 33 | 19 | 559 | 105 |
| GERN | GERON CORP | -490,335,614 | -$728.3M | 2 | 2 | 4 | 237 | 17 |
| CNC | CENTENE CORP | -457,989,439 | -$13.9B | 40 | 44 | 41 | 743 | 146 |
| AMGN | AMGEN INC | -410,943,144 | -$141.3B | 22 | 242 | 272 | 2456 | 646 |
| ZTS | ZOETIS INC | -393,314,109 | -$45.6B | 20 | 69 | 103 | 1362 | 223 |
| EW | EDWARDS LIFESCIENCES CORP | -384,241,367 | -$29.5B | 30 | 73 | 63 | 1064 | 216 |
| GEHC | GE HEALTHCARE TECHNOLOGY | -372,265,755 | -$25.8B | 20 | 54 | 73 | 1052 | 203 |
| GSK | GSK PLC-SPON ADR | -367,850,955 | -$18.6B | 14 | 68 | 51 | 840 | 181 |
| LFST | LIFESTANCE HEALTH GROUP INC | -367,649,718 | -$2.3B | 7 | 11 | 2 | 203 | 28 |
| DXCM | DEXCOM INC | -350,741,035 | -$21.3B | 15 | 45 | 47 | 828 | 132 |
| RXRX | RECURSION PHARMACEUTICALS-A | -333,963,981 | -$1.0B | 1 | 9 | 9 | 306 | 27 |
| FOLD | AMICUS THERAPEUTICS INC | -324,056,763 | -$4.5B | 0 | 0 | 1 | 292 | 1 |
| LXRX | LEXICON PHARMACEUTICALS INC | -323,348,415 | -$502.0M | 1 | 0 | 2 | 130 | 5 |
| NVO | NOVO-NORDISK A/S-SPONS ADR | -315,519,106 | -$10.8B | 33 | 77 | 69 | 1047 | 237 |
| TMO | THERMO FISHER SCIENTIFIC INC | -315,020,943 | -$149.5B | 31 | 177 | 211 | 2090 | 488 |
| MRNA | MODERNA INC | -303,697,037 | -$15.2B | 23 | 35 | 20 | 622 | 109 |
| LAB | STANDARD BIOTOOLS INC | -296,306,778 | -$272.0M | 3 | 4 | 1 | 147 | 8 |
| ISRG | INTUITIVE SURGICAL INC | -280,137,237 | -$121.5B | 14 | 135 | 171 | 1898 | 370 |
| SYK | STRYKER CORP | -275,669,912 | -$85.2B | 27 | 198 | 153 | 1838 | 448 |
| SHC | SOTERA HEALTH CO | -273,591,352 | -$3.7B | 4 | 15 | 5 | 263 | 32 |
| ERAS | ERASCA INC | -271,227,367 | -$4.0B | 3 | 8 | 3 | 211 | 14 |
| TSHA | TAYSHA GENE THERAPIES INC | -264,436,484 | -$1.2B | 1 | 2 | 0 | 182 | 8 |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | -263,844,462 | -$890.9M | 3 | 10 | 4 | 263 | 21 |
| BKD | BROOKDALE SENIOR LIVING INC | -252,903,156 | -$3.5B | 6 | 3 | 2 | 268 | 17 |
| EXEL | EXELIXIS INC | -252,892,581 | -$10.2B | 22 | 32 | 29 | 609 | 100 |
| BDX | BECTON DICKINSON AND CO | -252,366,921 | -$37.6B | 12 | 99 | 98 | 1194 | 260 |
| A | AGILENT TECHNOLOGIES INC | -246,767,763 | -$26.4B | 22 | 56 | 40 | 915 | 155 |
| BCRX | BIOCRYST PHARMACEUTICALS INC | -244,386,935 | -$2.3B | 6 | 8 | 3 | 279 | 23 |
| BHC | BAUSCH HEALTH COS INC | -231,681,122 | -$1.2B | 1 | 3 | 6 | 203 | 21 |
| NEOG | NEOGEN CORP | -229,927,978 | -$1.9B | 4 | 2 | 11 | 279 | 29 |
| IVVD | INVIVYD INC | -226,413,806 | -$292.3M | 0 | 0 | 0 | 136 | 2 |
| CI | THE CIGNA GROUP | -225,264,139 | -$58.3B | 15 | 99 | 94 | 1363 | 279 |
| VRTX | VERTEX PHARMACEUTICALS INC | -221,827,061 | -$96.7B | 32 | 113 | 84 | 1393 | 290 |